For example, an anticancer vaccine using a tumor-draining lymph node (tdLN)-targeting nanovaccine consisting of a tumor antigen showed robust cytotoxic CD8+ T cell responses, both locally and systemically, despite the immune-suppressed environment of tdLN [71]. Here, CD8A is linked to neoplasm.